抗体作製の各種受託サービスのご案内
「どこか安く請け負ってくれるところは?」
「免疫するだけじゃなくて、精製もして欲しい」
「モノクローナル抗体は、やはり高いかな」
など、お悩みの場合は是非一度、バイオロジカがお届けする抗体作製サービスの詳細について、こちらのリンクからホームページをご覧ください。
| Property | FAb fragments | ScFvs | sdAbs ** |
| Size | ~50 kDa (FAbs) | ~25 kDa | ~12 kDa |
| Proven commodity | +++ (several marketed) | +/– (late phase Clinical trials) | +/– (early phase clinical trials) |
| High affinity | + | +/– | +/– (depends on technology used) |
| Manufacturing | CHO, E. coli, yeasts | E. coli, yeasts | E. coli |
| Stability (e.g. pH, tempera xidation, shear stress) | + | +/– | ++ |
| Ease of purification | +/– | +/– | +/– |
| Potential for ambient temperature storage formulation | +/– | – | + |
| Alternative routes of administration (e.g. intranasal,inhalation) | – | +/– | + |
| Potential for blocking enzyme active sites | +/– | +/– | + (particularly nanobodies and IgNARs) |
| Tissue penetration | ++ | +++ | ++++ |
| Cavity binding | – | – | ++ |
| Manufacturable bi-, tri-, and multi-specificity | – | +/– | ++ |
| Effector functionality (e.g. ADCC, ADPC, CDC) | – | – | – |
| Serum half-life (without half-life extension technology) | < 1 h | < 1 h | < 1 h*** |
| Ability to extend half-life | +++ (up to ~10–12d with PEGylation)* | +++ (up to ~10–12 d with PEGylation)* | +++ (up to ~10–12d with PEGylation)*, *** |
| Potential for intracellular targeting | – | +/– | + (especially if disulfide bonds are removed) |
| Ease of manipulation | + | +/– (some aggregation issues) | + |
| Ability to dimerize or concatenate | – | + | ++ |
